US Food and Drug Administration approval overview in metastatic breast cancer
about
Antimitotic drugs in the treatment of cancerCyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.Taxanes for the treatment of metastatic breast cancer.Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.Trastuzumab in the Treatment of Breast Cancer.Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
P2860
Q26777317-24FEB7F9-E119-431A-A781-DFBDCE4EC0DBQ35742534-545A6EE9-9726-471B-A485-157B52EAE60DQ36364762-66FD1112-24E0-4795-A06E-C66C92900CDAQ36781543-50204805-8386-4F29-A045-8EEBED40F39AQ37123925-D79E19FC-86B2-4FC3-8D9F-F3C06051BEE1Q38739914-ACF0187C-B931-43EA-A17A-94C7816A563DQ54965603-6661E988-2D4C-4EB5-9FE3-1DE2604BCCB3
P2860
US Food and Drug Administration approval overview in metastatic breast cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
US Food and Drug Administration approval overview in metastatic breast cancer
@ast
US Food and Drug Administration approval overview in metastatic breast cancer
@en
type
label
US Food and Drug Administration approval overview in metastatic breast cancer
@ast
US Food and Drug Administration approval overview in metastatic breast cancer
@en
prefLabel
US Food and Drug Administration approval overview in metastatic breast cancer
@ast
US Food and Drug Administration approval overview in metastatic breast cancer
@en
P2093
P2860
P356
P1476
US Food and Drug Administration approval overview in metastatic breast cancer
@en
P2093
John Johnson
Patricia Cortazar
Patricia Keegan
Rajeshwari Sridhara
Richard Pazdur
Robert Justice
P2860
P304
P356
10.1200/JCO.2011.39.2613
P407
P577
2012-03-19T00:00:00Z